September 22, 2015 – Atopic dermatitis (or eczema) is a chronic inflammatory disorder associated with sleep disturbances and quality-of-life impairment. Sleep disturbances have been shown to cause headaches in childhood. However, an association between eczema and headaches is not well established.
September 21 – The National Eczema Association (NEA) has awarded Dr. Aaron Drucker, Assistant Professor, Department of Dermatology at Brown University, with the NEA Burden of Disease Research Audit grant, the findings of which will help to raise the profile of eczema as a serious disease, to deliver stronger, more united messages to insurers, medical providers and policy-makers on behalf of the eczema community.
August 17, 2015 – The National Eczema Association (NEA) is pleased to share news about a potential new topical non-steroidal treatment for mild-to-moderate eczema that you, the National Eczema Association community, helped make possible.
August 4, 2015 – The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD.
August 3, 2015 – Probiotic supplementation in pregnancy and early infancy can prevent infantile eczema, according to a review and meta-analysis published online July 21 in Allergy.
August 3, 2015 – In 1995, the American Academy of Pediatrics recommended routine vaccination against varicella zoster virus in the United States. Subsequently, rates of chickenpox infection have dramatically decreased in childhood. We sought to understand the impact of declining rates of chickenpox infection on the prevalence of eczema.
August 3, 2015 – Eczema is the same in any country, in any language. Enjoy this video from our friends in Brazil and share it if you can relate to this family’s story.
July 20, 2015 – Early nutrition and adiposity have been linked to atopic dermatitis (AD) development.
July 20, 2015 – Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug.
July 13, 2015 – Anacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis.